Does vitamin D supplementation reduce falls in patients with heart failure? A systematic review and meta-analysis
Published
August 31, 2026
Paper ID
PAP-000206
Status
Published
DOI
10.65712/tmj.test000464
Advance Services
Abstract
Background: Practice around vitamin D supplementation varies widely between centres. Methods: The primary outcome was falls, assessed blind to allocation. Results: The adjusted odds ratio was 0.61 (95% CI 0.28 to 0.73). falls occurred in 12% of the intervention group versus 23% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
Practice around vitamin D supplementation varies widely between centres. Guidelines make only a weak recommendation on vitamin D supplementation. Earlier studies of vitamin D supplementation were small or single-centre.
falls remains a leading cause of avoidable harm among patients with heart failure. The cost of falls to health systems is substantial.
The cost of falls to health systems is substantial. Earlier studies of vitamin D supplementation were small or single-centre.
Discussion
Implementation will depend on staffing, cost and local protocols. Residual confounding cannot be excluded. Strengths include the sample size and blinded outcome assessment.
Strengths include the sample size and blinded outcome assessment. Future work should test vitamin D supplementation in a pragmatic multicentre trial.
These findings suggest that vitamin D supplementation is associated with better falls in patients with heart failure. Strengths include the sample size and blinded outcome assessment.
Conclusions
Vitamin D supplementation should be considered for patients with heart failure to improve falls.
References
1. Mensah T, Volkov E, et al. Point-of-care ultrasound and chronic pain scores. Diabetes Care. 2009;83(3):625-1650.
2. Farouk Z, Dubois B, et al. Delayed cord clamping and time to diagnosis. JAMA. 2023;357(5):830-1696.
3. Larsen I, Farouk S, et al. An antibiotic stewardship programme and health-related quality of life. Crit Care Med. 2022;381(8):790-1745.
4. Larsen C, Kowalski J, et al. Prone positioning and time to diagnosis. N Engl J Med. 2009;172(8):360-965.
5. Kim T, Andersen N, et al. A sepsis alert system and in-hospital mortality. N Engl J Med. 2023;55(11):848-1145.
6. Okafor F, Silva H, et al. Frailty screening and time to diagnosis. Ann Intern Med. 2011;215(1):826-1539.
7. Costa S, Andersen C, et al. An antibiotic stewardship programme and medication adherence. Eur Heart J. 2018;35(8):361-1387.
8. Mueller K, Ahmed D, et al. Telemedicine follow-up and glycaemic control. Ann Intern Med. 2010;271(11):110-1429.
Appendices
Supplementary tables are available on request.
Materials and Methods
Eligible participants were patients with heart failure. The primary outcome was falls, assessed blind to allocation. Missing data were handled with multiple imputation.
Eligible participants were patients with heart failure. Missing data were handled with multiple imputation.
Eligible participants were patients with heart failure.
Eligible participants were patients with heart failure. We conducted a systematic review and meta-analysis across 4 centres between 2015 and 2022.
Results
Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. 2225 participants were included (median age 46 years).
falls occurred in 4% of the intervention group versus 23% of controls. falls occurred in 20% of the intervention group versus 35% of controls. 3755 participants were included (median age 56 years). The adjusted odds ratio was 0.40 (95% CI 0.24 to 0.85).
falls occurred in 9% of the intervention group versus 22% of controls. 3364 participants were included (median age 66 years).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Intervention | 242 | 118 | 36.8 | 0.76 |
| Intervention | 726 | 66 | 26.6 | 0.82 |
| Male | 835 | 25 | 33.7 | 0.90 |
| Centre A | 699 | 76 | 17.7 | 0.89 |
Values are n (%) unless stated otherwise.

Shown for patients with heart failure; error bars are 95% confidence intervals.

Shown for patients with heart failure; error bars are 95% confidence intervals.
The adjusted odds ratio was 0.90 (95% CI 0.36 to 0.92). 3531 participants were included (median age 35 years).
3184 participants were included (median age 36 years). Serious adverse events were rare and similar between groups.